Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes

Indian Journal of Pharmacology

Volumn 41, Issue 4, 2009, Pages 197-198

  Mahajan, Rajiv ^a  

^a AIMSR   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE MESILATE;

ARTICLE; DIABETIC PATIENT; DIZZINESS; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SYNCOPE; TREATMENT OUTCOME; VOMITING;

EID: 70349843955     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.56070     Document Type: Article

References (5)

1. Waknine Y. FDA approvals: Fanapt and cycloset. Medscape CME 2009. Available from: http://www.cme.medscape.com/viewarticle/702793. [cited 2009 May 24]
2. Gaziano JM. Quick-release bromocriptine has favorable cardiovascular safety profile. Proceedings of the 67th Annual Scientifi c Sessions of the American Diabetes Association; 2007 Jun 22-26; Chicago, Illinois, USA. [press release] Chicago: PRNewswire; 2007 Jun 23.
3. Hennessy T. Old Parkinson's drug tweaked into diabetes treatment. The Associated Press; 2009 May 7.
4. U.S. Food and Drug Administration. Cycloset Prescribing Information. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 020866lbl.pdf. [cited 2009 May 21]
5. Bromocriptine mesylate approved for treatment of type 2 diabetes. Endocrinetoday 2009 In press.